E
XTL Biopharmaceuticals Ltd. XTLB
$1.23 -$0.01-0.81%
Recommendation
Sell
Prev Close
$1.24
Volume
6,269
Avg Vol (90D)
8,893
Market Cap
$10.99M
Dividend & Yield
--
52-Week Range
$1.09 - $3.48
P/E (TTM)
--
EPS (TTM)
-$0.0036
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
XTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional Challenges
12/31/2024 - TipRanks Financial Blog
XTL Biopharmaceuticals Reports Financial Results Amid Regional Unrest
12/31/2024 - TipRanks Financial Blog
XTL Biopharmaceuticals Adjusts Shares, Eyes Expansion
11/19/2024 - TipRanks Financial Blog
XTL Biopharmaceuticals Resolves Dispute with Social Proxy
11/12/2024 - TipRanks Financial Blog
XTL Biopharmaceuticals Expands with AI Company Acquisition
8/14/2024 - TipRanks Financial Blog
XTL Biopharmaceuticals completes acquisition of The Social Proxy
8/14/2024 - The Fly
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
8/14/2024 - Globe Newswire
XTL Biopharmaceuticals Announces Shareholder Meeting Outcomes
7/22/2024 - TipRanks Financial Blog
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
6/17/2024 - InvestorPlace
XTL Biopharmaceuticals Acquires SOCIAL PROXY LTD.
6/5/2024 - TipRanks Financial Blog
XTL Biopharmaceuticals to acquire The Social Proxy
6/5/2024 - The Fly
XTL Entered Definitive Agreement to Acquire The Social Proxy
6/5/2024 - Globe Newswire
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
5/13/2024 - InvestorPlace
XTL Biopharmaceuticals Shareholder Meeting Outcomes
4/30/2024 - TipRanks Financial Blog
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
4/29/2024 - InvestorPlace
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$764.20K
EBIT (TTM)
-$765.00K
Net Income (TTM)
-$1.78M
Balance Sheet
Total Assets (Q)
$2.43M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$206.00K
Book Value Per Share (Q)
$0.0041
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Tuesday, April 30, 2024
Period Date
Sunday, December 31, 2023
Next Filing
(est)
Price History
Created with Highstock 5.0.142. Dec16. Dec30. Dec13. Jan27. Jan10. Feb24. Feb10. Mar24. Mar$1.00$2.00$3.00Price as of Apr 02, 2025
Beta
0.66
7-Day Total Return
11.82%
30-Day Total Return
-18.54%
60-Day Total Return
-39.16%
90-Day Total Return
-30.51%
Year to Date Total Return
-37.56%
1-Year Total Return
-63.06%
2-Year Total Return
-5.38%
3-Year Total Return
-46.75%
5-Year Total Return
23.52%
52-week Low
Mar 27, 2025 - $1.09
52-week High
Apr 03, 2024 - $3.48
Valuation
Market Cap
$10.99M - Nano Cap
Enterprise Value
$9.26M
Price/Sales (TTM)
--
Price/Book (Q)
302.44
Dividends and Shares
Shares Outstanding
544.91M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.xtlbio.com
Phone Number
972 3 611 6600
Address
26 Ben-Gurion St.
Ramat Gan, 5112001
Country
Israel
Year Founded
1993
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug... more
NASDAQ 04/03/2025 2:30PM Eastern Quotes delayed
Weiss Ratings